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hournal of Infection and Public Health (2012) 5, S1ntroductionhe  management  of  non-small  cell  lung  cancer  is
apidly evolving  toward  personalized  therapy  based
n molecular  markers.  This  advancement  was  facil-
tated by  the  development  of  targeted  therapy  that
as proven  efﬁcacious  in  clinical  trials.  The  avail-
bility of  newer  therapies  and  the  incorporation  of
arkers in  the  treatment  decision  will  have  impact
n the  standard  of  care,  not  in  that  setting  only  but
lso in  the  subsequent  lines  of  therapy.
The  Saudi  Lung  Cancer  Guidelines  published  in
his Journal  are  the  result  of  efforts  by  mul-
idisciplinary team  members  representing  Saudi
ung Cancer  Group  in  Saudi  Thoracic  Society  (STS)
nd Saudi  Oncology  Society  (SOS)  and  represent-
ng various  tertiary  institutions  in  the  Kingdom.
hese guidelines  incorporated  the  latest  evidences
merged  from  recent  trials  and  took  into  account
ny relevant  regional  issues.
Many thanks  to  all  members  of  this  group  and  we
re looking  to  any  constructive  feedback  from  our
eaders.
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